TCTMD’s Top 10 Most Popular Stories for November 2017
The ORBITA study was the hands-down winner for top story this month, but our story on the new hypertension guidelines was also a top contender.
The ORBITA study, presented at TCT 2017, was the hands-down winner for top story in November, but the new hypertension guidelines, released just a week and a half later at the American Heart Association (AHA) 2017 Scientific Sessions, also were a top contender. Other big studies from both meetings round out the list, including DAPT-STEMI and REDUCE, FAME 2 at 3 years, and CULPRIT-SHOCK
The intriguing study, which hinted at a placebo effect of PCI, left physicians debating the merits of revascularization in stable coronary artery disease.
The treatment goal has been lowered, and a new classification expands the number of US adults considered to have hypertension.
DAPT-STEMI and REDUCE found 3 and 6 months of DAPT, respectively, were noninferior to the standard 12 months of treatment.
The study found strikingly fewer urgent revascularizations and numerically fewer deaths and MIs in the PCI group when fractional flow reserve was gatekeeper.
The results, which challenge current guidelines and appropriate use criteria, will change practice, several experts agreed.
While two analyses suggest the thrombotic risk can be mitigated, others say the data are “frustrating” in that there’s still not even a hint of benefit.
A chorus of interventionalists all agreed that BMS have an extremely limited role, if any, in clinical practice following results of several studies.
This is an important, rigorously conducted study in an area that is sorely in need of good data, Sunil Rao says.
Lingering questions about the potential for residual ischemic stroke risk with the LAA closure device temper enthusiasm for its use.
Features and Opinion
Beyond the news, there was plenty of noteworthy editorial content in other sections of the site.